The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Oncology Biomarkers Market By 2030 Starting From Its 2026 Size?
The oncology biomarkers market has experienced significant expansion recently. This market is projected to expand from $17.3 billion in 2025 to $19.73 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. Historically, this growth was driven by factors such as the broadening of cancer screening initiatives, progress in molecular biology research, wider access to biomarker testing technologies, an increase in oncology clinical trials, and enhanced partnerships between research bodies and healthcare facilities.
The oncology biomarkers market is projected to experience substantial expansion in the coming years. This market is set to reach a valuation of **$33.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%**. Factors contributing to this anticipated growth include a heightened demand for tailored oncology treatments, the wider application of AI in biomarker identification, increased financial commitments to cancer genomics, the growing acceptance of liquid biopsy techniques, and an enhanced emphasis on early cancer diagnosis and surveillance. Key developments expected during this period involve the increasing uptake of precision oncology diagnostic tools, a greater reliance on genetic and protein biomarkers, the deeper incorporation of bioinformatics into biomarker assessment, the broadening of companion diagnostics initiatives, and a sharpened focus on individualized cancer therapy.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp
What Primary Drivers Are Shaping The Development Of The Oncology Biomarkers Market?
The increasing occurrence of cancer is projected to fuel expansion within the oncology biomarker market in the future. Cancer is defined as a condition where certain body cells multiply without regulation and progressively disseminate throughout the body. Oncological biomarkers offer deeper insights into the specific cancer type through analysis of genes, proteins, and other biological materials present in an individual. As an illustration, in February 2024, data from the World Health Organization, an intergovernmental body based in Switzerland, indicated that by 2050, new cancer cases are anticipated to exceed 35 million, marking a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing prevalence of cancer is a key factor propelling the development of the oncology biomarkers market.
Which Segment Categories Define The Oncology Biomarkers Market?
The oncology biomarkers market covered in this report is segmented –
1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types
2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types
3) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
4) By End-User: Hospitals, Academic And Cancer Research Institutes, Diagnostic Laboratories
Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers
2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)
3) By Other Biomarker Types: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers
What Major Market Trends Are Driving Changes In The Oncology Biomarkers Market?
Major companies in the oncology diagnostics market are actively developing advanced biomarker-based assays to enhance early cancer detection, monitor minimal residual disease (MRD), and assess patient responses to therapies. Minimal residual disease refers to the small number of cancer cells that can remain in the body post-treatment, potentially leading to recurrence if not identified. For example, in May 2024, Tempus, a US-based artificial intelligence and precision medicine company, unveiled its MRD test portfolio, which features the xM test and the xM (NeXT Personal Dx) test, both developed by Personalis. This portfolio encompasses both tumor-naïve and tumor-informed assays, engineered to detect early cancer recurrence and residual disease, and to track patient response to immunotherapy. By harnessing circulating tumor biomarkers, these assays provide clinicians with crucial and actionable insights to guide patient management.
Who Are The Top Companies Competing In The Oncology Biomarkers Market?
Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA
Read the full oncology biomarkers market report here:
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report
How Does The Oncology Biomarkers Market Perform Across Major Global Regions?
North America was the largest region in the oncology biomarkers market in 2025. The regions covered in the oncology biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Oncology Biomarkers Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp
Browse Through More Reports Similar to the Global Oncology Biomarkers Market 2026, By The Business Research Company
Cancer Biomarker Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Clinical Oncology Next Generation Sequencing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model